Zinacef 250 mg Norvegia - norvegiană - Statens legemiddelverk

zinacef 250 mg

sandoz a/s - cefuroksimnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 250 mg

Ibuprofen Zentiva 200 mg Norvegia - norvegiană - Statens legemiddelverk

ibuprofen zentiva 200 mg

zentiva k.s. - ibuprofen - tablett, filmdrasjert - 200 mg

Exparel liposomal Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

exparel liposomal

pacira ireland limited - bupivacaine - acute pain - amides, anesthetics, local - exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.

Vetflurane 1000 mg/ g Norvegia - norvegiană - Statens legemiddelverk

vetflurane 1000 mg/ g

virbac s.a. - isofluran - væske til inhalasjonsdamp - 1000 mg/ g

Methotrexate Pfizer 25 mg/ ml Norvegia - norvegiană - Statens legemiddelverk

methotrexate pfizer 25 mg/ ml

pfizer as - metotreksat - injeksjons-/infusjonsvæske, oppløsning - 25 mg/ ml

Bronkyl 200 mg Norvegia - norvegiană - Statens legemiddelverk

bronkyl 200 mg

karo pharma as - acetylcystein - brusetablett - 200 mg

Bronkyl forte 600 mg Norvegia - norvegiană - Statens legemiddelverk

bronkyl forte 600 mg

karo pharma as - acetylcystein - brusetablett - 600 mg

Isocare Vet 1000 mg/ g Norvegia - norvegiană - Statens legemiddelverk

isocare vet 1000 mg/ g

ecuphar nv - isofluran - væske til inhalasjonsdamp - 1000 mg/ g

Adempas Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hypertensjon, pulmonal - antihypertensive midler for pulmonal arteriell hypertensjon - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har vært vist i en pah befolkningen, herunder aetiologies av idiopatisk eller heritable pah eller pah assosiert med bindevev sykdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Pedea Uniunea Europeană - norvegiană - EMA (European Medicines Agency)

pedea

recordati rare diseases - ibuprofen - ductus arteriosus, patent - hjertetapi - behandling av en hemodynamisk signifikant patentsduktus arteriosus hos premature nyfødte spedbarn mindre enn 34 uker med graviditetsalder.